Clinical Trials

103 enrolled

Carcinoma, Transitional Cell

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Urinary Bladder Neoplasms

NCT03967977 2026-04-15

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

420 enrolled

Phase 4 Active not recruiting

Carcinoma, Transitional Cell

NCT04597125 2026-04-15

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

654 enrolled

Phase NA Active not recruiting

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT04905069 2026-04-15

SABRE

500 enrolled

GenitourinaryGynecologicThoracic

Neoplasms, Prostatic Neoplasms

NCT05397093 2026-04-15

ITIL-306 in Advanced Solid Tumors

Phase 1 Terminated

1 enrolled

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms

NCT05483868 2026-04-15

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05581004 2026-04-15

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

450 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06010914 2026-04-15

DADOX

Active not recruiting

100 enrolled

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06136650 2026-04-15

MK-5684-004

1,314 enrolled

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT06225596 2026-04-15

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

956 enrolled

Urinary Bladder Neoplasms

NCT06511141 2026-04-15

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Phase NA Recruiting

150 enrolled

Prostatic Hyperplasia, Prostatic Neoplasms, Urinary Bladder, Overactive

NCT07106762 2026-04-15

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Phase 2/3 Recruiting

470 enrolled

Urinary Bladder Neoplasms

NCT07223372 2026-04-15

TARA

Recruiting

1,000 enrolled

Metastatic Hormonesensitive Prostate Cancer (mHSPC)

NCT07236112 2026-04-15

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

6 enrolled

Prostatic Neoplasms

NCT07475806 2026-04-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Recruiting

240 enrolled

Phase 1 Not yet recruiting

Muscle-invasive Bladder Cancer

NCT07518043 2026-04-15

A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

174 enrolled

DermatologicGenitourinary

Carcinoma, Transitional Cell, Melanoma

NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT03528694 2026-04-14

POTOMAC

1,018 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04122976 2026-04-14

DAROL

Active not recruiting

805 enrolled

Prostatic Neoplasms

NCT04960709 2026-04-14

VOLGA

712 enrolled

Urinary Bladder Neoplasms

NCT05847166 2026-04-14

A Phase 2/3,PSMA-T4, Prostate Cancer

Phase NA Recruiting

80 enrolled

Prostatic Neoplasms

NCT06011954 2026-04-14

A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

Recruiting

202 enrolled

Urinary Bladder Neoplasms

NCT06026410 2026-04-14

FIT-001

GastrointestinalGenitourinaryThoracic

300 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Colorectal Neoplasms

NCT06122584 2026-04-14

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

380 enrolled

Prostatic Neoplasms

NCT06334120 2026-04-14

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Recruiting

600 enrolled

Non-metastatic Castration-resistant Prostate Cancer

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Available

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT07195916 2026-04-14

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

DermatologicGenitourinaryLymphoidOther hematologic neoplasm

280 enrolled

Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT07225946 2026-04-14

KLK2-PASenger

800 enrolled

Phase 2 Not yet recruiting

Prostatic Neoplasms, Castration-Resistant

NCT07450599 2026-04-14

CHINANEO

250 enrolled

Phase 1/2 Not yet recruiting

High-Risk Localized Prostate Cancer

NCT07529717 2026-04-14

CRIUS-1

42 enrolled

Prostatic Neoplasms

NCT01946204 2026-04-13

SPARTAN

1,207 enrolled 15 charts 2 FDA

Prostatic Neoplasms

NCT02123758 2026-04-13

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

57 enrolled

Prostatic Neoplasms

NCT02257736 2026-04-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02365597 2026-04-13

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

239 enrolled 32 charts 2 FDA

Urothelial Cancer

NCT02489318 2026-04-13

TITAN

1,052 enrolled 13 charts 2 FDA

Prostatic Neoplasms

NCT02531516 2026-04-13

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

1,503 enrolled

Prostatic Neoplasms

NCT02592317 2026-04-13

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

23 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT02960022 2026-04-13

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Phase 2 Recruiting

900 enrolled

Prostatic Neoplasms

NCT03390504 2026-04-13

THOR

629 enrolled 32 charts 1 FDA

Phase 2 Active not recruiting

Urothelial Cancer

NCT03431350 2026-04-13

QUEST

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT03523442 2026-04-13

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

19 enrolled